[Research] Celltrion (068270) – SK Securities | 2Q26 Re: Profitability Inflection Underway · Operating Leverage In Focus · Robust H2 Momentum / 2026-08-03
Brokerage : SK Securities Analyst : Seonkyoung Lee Investment Rating : BUY (Maintained) Target Price : KRW 247,823 (Maintained) Core Momentum : Operating leverage begins in earnest as high-margin new products expand to 65% of total sales, delivering a strong 2Q26 earnings beat with sustained growth expected from Zymfentra’s Pfizer collaboration and Omlyclo’s US launch….